Last $85.88 USD
Change Today -1.44 / -1.65%
Volume 3.6M
As of 5:20 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Open
$86.52
Previous Close
$87.32
Day High
$87.19
Day Low
$84.84
52 Week High
03/2/15 - $89.88
52 Week Low
04/15/14 - $53.62
Market Cap
15.2B
Average Volume 10 Days
2.3M
EPS TTM
$1.68
Shares Outstanding
177.5M
EX-Date
--
P/E TM
51.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDO INTERNATIONAL PLC (ENDP)

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men’s and women’s health, and prostate health. The company’s products also include Aveed, an injectable testosterone preparation to treat male hypogonadism; and BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $4.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $157.0K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $562.0K
Chief Operating Officer of Pharmaceuticals
Total Annual Compensation: $270.8K
Compensation as of Fiscal Year 2013.

endo international plc (ENDP) Key Developments

Endo International plc Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for Fiscal 2015

Endo International plc reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. The company reported revenue of $799,957,000, operating loss of $72,668,000, loss from continuing operations before income tax of $119,917,000, net loss attributable to company of $53,483,000 or $0.35 per diluted share against revenue of $584,946,000, operating loss of $732,481,000, loss from continuing operations before income tax of $775,061,000, net loss attributable to company of $775,910,000 or $6.74 per diluted share a year ago. Non-GAAP net income was $184,884,000 or $1.16 per diluted share against $123,697,000 or $0.96 per diluted share a year ago. The decrease in net sales is primarily attributable to a year-over-year decrease in demand due to generic competition. For the year, the company reported revenue of $2,877,188,000, operating loss of $896,943,000, loss from continuing operations before income tax of $1,125,701,000, net loss attributable to company of $721,319,000 or $4.91 per diluted share against revenue of $2,616,907,000, operating loss of $425,625,000, loss from continuing operations before income tax of $559,567,000, net loss attributable to company of $685,339,000 or $6.05 per diluted share a year ago. Net cash provided by operating activities was $337,776,000 against $298,517,000 a year ago, Purchases of property, plant and equipment was $80,251,000 against $94,626,000 a year ago. Non-GAAP net income was $674,898,000 or $4.31 per diluted share against $573,996,000 or $4.79 per diluted share a year ago. For the full twelve months ended December 31, 2015, at current exchange rates, the company estimates total revenue to be between $2.90 billion and $3.00 billion. Reported (GAAP) diluted EPS from continuing operations to be between $2.73 and $2.93. Adjusted diluted earnings per share from continuing operations to be between $4.35 and $4.55. Adjusted diluted earnings per share assume full year adjusted diluted shares outstanding of 180 million. The company's 2015 guidance is based on certain assumptions including: adjusted gross margin of between 63% and 65%, adjusted interest expense of approximately $310 million and adjusted effective tax rate of between 15% and 17%. The company expects corporate gross margin as a percentage of revenues to be between 63% and 65% in 2015. The company expects adjusted interest expense in 2015 of approximately $310 million. Adjusted basis, the company expects corporate gross margin as a percentage of revenues to be between 63% and 65% in 2015.

Endo International Considers Strategic Alternatives For American Medical System

American Medical Systems is exploring various strategic alternatives for women's health business of its American Medical Systems Holdings Inc.

Endo International plc to Report Q4, 2014 Results on Mar 02, 2015

Endo International plc announced that they will report Q4, 2014 results Pre-Market on Mar 02, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $85.88 USD -1.44

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $167.18 USD -1.12
Edwards Lifesciences Corp $134.58 USD -1.27
Intuitive Surgical Inc $509.07 USD +5.82
Mallinckrodt PLC $114.85 USD -3.97
UCB SA €67.39 EUR -1.56
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit www.endo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.